UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market

UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market

Source: 
CP Wire
snippet: 

UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercializing antibiotics in the US, announced on 5/15/18 the signature of an exclusive license agreement for the antibiotics mecillinam and pivmecillinam with LEO Pharma A/S. The license agreement provides UTILITY with exclusive access to LEO Pharma’s complete dataset for both products, for the purpose of gaining approval of the products in the US.